Drug intelligence / Profile preview

IL-OTM

Development stage: Preclinical
Lead developer: PARAS Biopharma
Modality: Recombinant Proteins and Enzymes
Administration: Transdermal

Overview

IL-OTM (PB(OA)-5010) is a recombinant protein biobetter developed by Paras Biopharmaceuticals for the treatment of osteoarthritis. It is designed as a transdermal patch formulation that targets the Interleukin-1 receptor (IL-1R). By blocking IL-1R, the drug aims to modulate the inflammatory and catabolic processes driven by IL-1, which are central to the progression of joint degradation in osteoarthritis. The transdermal patch delivery system is intended to provide localized or systemic delivery of the therapeutic protein, potentially improving patient compliance and reducing side effects compared to systemic injections. It is currently in the preclinical stage of development.

Other names: PB(OA)-5010IL-OTM

Targets

IL-1R (Interleukin-1 receptor type 1 (IL-1R1))

Beyond the preview

Go deeper on IL-OTM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL-OTM.

Explore the full profile